Walvax Biotechnology Co., Ltd. (SHE:300142)

Walvax Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	1,681	3,764	4,365	3,873	3,443	1,962
Cash & Short-Term Investments	1,681	3,764	4,365	3,873	3,443	1,962
Cash Growth	-53.59%	-13.77%	12.68%	12.49%	75.54%	-17.62%
Accounts Receivable	2,284	2,410	3,101	3,577	2,481	2,004
Other Receivables	394.22	58.8	114.18	416.13	774.86	304.77
Receivables	2,678	2,468	3,215	3,993	3,255	2,308
Inventory	545	752.59	1,035	995.81	873.59	483.56
Other Current Assets	1,008	82.22	119.21	86.25	107.94	26.77
Total Current Assets	5,912	7,067	8,733	8,948	7,680	4,780
Property, Plant & Equipment	4,042	4,079	3,768	3,161	2,604	1,590
Long-Term Investments	984.99	1,638	1,057	1,292	1,491	1,605
Goodwill	33.66	33.66	33.66	33.66	33.66	33.66
Other Intangible Assets	858.23	1,035	1,086	1,167	434.98	271.68
Long-Term Accounts Receivable	3.6	7.27	-	-	-	-
Long-Term Deferred Tax Assets	103.84	104.56	103.44	124.84	168.01	138.55
Long-Term Deferred Charges	555.89	513.86	473.48	309.38	1,022	890
Other Long-Term Assets	756.93	246.62	333.54	300.2	240.63	329.41
Total Assets	13,252	14,724	15,589	15,336	13,674	9,638
Accounts Payable	1,338	1,568	1,805	1,836	1,258	607.79
Accrued Expenses	30.2	549.81	722.05	1,145	754.71	497.41
Short-Term Debt	-	-	320.27	97.18	310	40
Current Portion of Long-Term Debt	18.6	38.98	8.79	-	-	-
Current Portion of Leases	-	7.85	21.88	23.35	4.6	-
Current Income Taxes Payable	23.53	-	14.13	19.47	2.03	68.54
Current Unearned Revenue	28.47	106.18	160.47	192.96	35.29	9.68
Other Current Liabilities	239.78	99.4	151.25	194.15	870.61	198.55
Total Current Liabilities	1,678	2,370	3,204	3,509	3,235	1,422
Long-Term Debt	234	433.34	434.9	314.24	-	-
Long-Term Leases	19.65	11.77	20.6	27.74	1.06	-
Long-Term Unearned Revenue	256.65	278.44	423.33	404.53	344.3	256.18
Long-Term Deferred Tax Liabilities	65.54	55.91	68.71	90.94	94.56	112.27
Other Long-Term Liabilities	54.4	67	42.08	-	-	-
Total Liabilities	2,309	3,216	4,194	4,346	3,675	1,790
Common Stock	1,599	1,599	1,607	1,607	1,601	1,546
Additional Paid-In Capital	4,549	4,549	4,900	4,965	4,772	3,262
Retained Earnings	3,257	3,110	2,984	2,580	1,895	1,546
Treasury Stock	-	-	-358.63	-286.42	-	-
Comprehensive Income & Other	277.53	171.28	217.18	217.18	216.33	190.88
Total Common Equity	9,683	9,430	9,349	9,084	8,484	6,545
Minority Interest	1,260	2,078	2,046	1,906	1,515	1,303
Shareholders' Equity	10,943	11,508	11,395	10,990	9,999	7,848
Total Liabilities & Equity	13,252	14,724	15,589	15,336	13,674	9,638
Total Debt	272.24	491.94	806.42	462.51	315.67	40
Net Cash (Debt)	1,409	3,272	3,558	3,411	3,128	1,922
Net Cash Growth	-51.37%	-8.05%	4.31%	9.06%	62.77%	-19.30%
Net Cash Per Share	0.88	2.05	2.22	2.13	1.99	1.23
Filing Date Shares Outstanding	1,599	1,599	1,599	1,601	1,601	1,546
Total Common Shares Outstanding	1,599	1,599	1,599	1,601	1,601	1,546
Working Capital	4,234	4,697	5,529	5,440	4,445	3,358
Book Value Per Share	6.05	5.90	5.85	5.67	5.30	4.23
Tangible Book Value	8,791	8,361	8,230	7,883	8,016	6,239
Tangible Book Value Per Share	5.50	5.23	5.15	4.92	5.01	4.04
Buildings	-	953.95	948.5	767.91	541.68	487.84
Machinery	-	2,196	2,093	1,580	1,235	930.76
Construction In Progress	-	2,114	1,645	1,509	1,527	762.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.